iBio receives Nasdaq deficiency notice for bid price below $1.00, has 180 days to cure

iBio, Inc.

Received Nasdaq notice on July 29, 2025 for failing Minimum Bid Price of $1.00 for 30 consecutive business days.
Company has until January 26, 2026 to regain compliance by closing at $1.00+ for at least 10 consecutive business days.
If not cured, iBio may be eligible for additional 180 days if it meets other standards and notifies Nasdaq of intent to cure via reverse split.
No immediate effect on listing; stock continues trading on Nasdaq Capital Market under 'IBIO'.
Company intends to monitor bid price and consider options including reverse stock split.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.